Please select the option that best describes you:

For a patient with triple-class-refractory myeloma and cytopenias who has been collected for CAR-T, would you choose aggressive chemotherapy or a bispecific antibody for bridging?  

This question seems quite specific but happens quite often. Multi-drug chemotherapy runs the risk of profound cytopenias and infections, while bispecifics (either BCMA or GPRC5D) have theoretical risks and unknown efficacy.



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
These are both excellent responses - thank you, @B...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution